Abstract
BackgroundTeriflunomide and dimethylfumarate are two new oral therapies for relapsing-remitting multiple sclerosis (RRMS). Due to the increase in patients with these treatments, face-to-face interviews were carried out with these patients...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have